Reference entry

Dulaglutide

Also listed as Trulicity

Read the scope, examine the source, and keep your own question alongside the evidence.

Status labels apply within the product, route, and use described below. Read the limitations alongside that scope.

Scoped product status: Approved product
Evidence label: Randomized evidence

Status as of 2026-10-27

Reference fields

Sources for these fields

Product and use: Trulicity: specified type 2 diabetes populations.
Route context: Subcutaneous injection.
Mechanism: GLP-1 receptor agonist fusion protein.
Evidence: Randomized studies.
Limitations: No weight-management indication.
Safety: Not recommended for severe gastroparesis.

From a report to your question

Decide what you want an outcome to describe before interpreting its label. A question about an experience, a change in a measured quantity, and an explanation for that change asks for different information. Inspect the report's definition and the way observations were recorded. If a claim turns a recorded symptom into evidence of a treatment result, look for the reasoning that connects those propositions. Keep the experience and the proposed explanation distinct, so an important concern can remain visible without being treated as proof of a cause.

Questions to consider

What exactly does the recorded outcome describe in this report?
Does the claim concern an experience, a measured change, or its cause?
What evidence connects the observation with the explanation being offered?

Sources

These references support the fields as a group. Follow a source to check the original wording and its scope.

TRULICITYNLM · Checked 2026-10-27

Continue reading

Reading topics: Metabolism. These organize the library and do not describe recommended uses.

Educational reference information. No clinician review is claimed. This entry does not provide personal medical advice.